Release Date: February 07, 2019
Expiration Date: February 07, 2020

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Oncology nurses face a number of challenges when treating patients with myelodysplastic syndromes. For one, it can be difficult to navigate between the emerging therapies and diagnostic guidelines. In this activity, Dr. Patel will address strategies for applying next-generation sequencing in the management of patients with MDS. Another challenge nurses face is the molecular basis of MDS and its requirements for diagnosis. Dr. Padron discusses which diagnostic criteria to utilize in your practice.

Target Audience

This activity is designed for nurses in the community setting who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Apply next-generation sequencing in practice for the management of patients with MDS
• Differentiate between various classifications of diseases within the MDS spectrum
• Incorporate clinical guidelines into the diagnostic approach for patients with suspected MDS

Agenda

Making the Right Diagnosis: Applying Next-Generation Sequencing (NGS) in MDS – Jay L. Patel, MD

Diagnostic Challenges in MDS – Eric Padron, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 07, 2020. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Jay L. Patel, MD
Associate Professor and Medical Director
University of Utah and ARUP Laboratories
Salt Lake City, Utah

Dr. Jay Patel received his medical degree from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. He then served as a hematopathology fellow at Stanford University. Dr. Patel is an Associate Professor of Pathology and Medical Director at the University of Utah School of Medicine.

Dr. Patel is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology, and is a member of the CAP Hematology & Clinical Microscopy Resource Committee. His clinical and research interests are broad and include all aspects of hematopathology. He specializes in application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.

Eric Padron, MD
Assistant Member
Malignant Hematology Department
H. Lee Moffitt Cancer Center
Tampa, Florida

Dr. Eric Padron received his medical degree from the University of Florida in Gainesville. He completed his internal medicine residency at University of Florida, and his hematology/oncology fellowship at Moffitt Cancer Center, University of South Florida. He is an Assistant Member in the Malignant Hematology Department at the H. Lee Moffitt Cancer Center in Tampa, Florida, as well as Section Head of Genomics and Personalized Medicine.

Dr. Padron is a founding member of MDS/MPN International Working Group and is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research focus is in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). His applied translational laboratory seeks to identify and implement novel discoveries directly to the clinic. Dr. Padron has successfully translated his laboratory discoveries into several trials in the CMML clinic. This is exemplified by his bench-to-bedside efforts that have led to the successful completion of a phase 1 and 2 trial testing ruxolitinib in CMML.

Accreditation

NURSING CREDIT Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-008-098

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Eric Padron has received grant support related to research activities from Humanagen, Incyte Corporation, and Kura Oncology, Inc.

Dr. Jay Patel has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.